<DOC>
	<DOCNO>NCT00357396</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy drug , busulfan , melphalan , thiotepa , donor stem cell transplant help stop growth tumor cell prepare patient 's bone marrow stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal tissue . Giving tacrolimus , sirolimus , mycophenolate mofetil may stop happen . PURPOSE : This phase II trial study well give busulfan together melphalan thiotepa follow donor stem cell transplant work treat patient high-risk Ewing 's tumor .</brief_summary>
	<brief_title>Busulfan , Melphalan , Thiotepa Followed By Donor Stem Cell Transplant Treating Patients With High-Risk Ewing 's Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate disease-free overall survival patient high-risk tumor Ewing 's family treat unmodified T-cell deplete allogeneic hematopoietic stem cell transplantation cytoreduction comprise busulfan , melphalan , thiotepa . - Determine regimen-related morbidity mortality patient . - Determine incidence acute chronic graft-vs-host disease patient treat regimen . - Determine biologic response minimal residual disease patient treat regimen . OUTLINE : This prospective study . - Myeloablative preparative regimen : Patients receive busulfan IV 2 hour every 6 hour day -8 -6 , melphalan IV 20 minute day -5 -3 , thiotepa IV 4 hour day -2 . - Allogeneic hematopoietic stem cell transplant : Patients undergo allogeneic bone marrow T-cell deplete peripheral blood stem cell transplantation day 0 . - Graft-vs-host disease ( GVHD ) prophylaxis : Patients receive treatment accord institutional guideline give treatment infection . After completion study treatment , patient follow periodically least 3 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis highrisk tumor Ewing 's family define 1 following : Biopsyproven disease distant metastases site lung Relapsed disease completion prior standard frontline therapy highdose chemotherapy Currently complete remission ( CR ) evidence disease ( without minimal residual disease ) good partial remission ( i.e. , CR abnormal bone scan ) prior standard highdose chemotherapy local control HLAcompatible stem cell donor available Compatible donor include match HLAA , B , C , DR 1 2 DQ allele highresolution molecular typing Related unrelated donor PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) 70100 % ( ≥ 16 year old ) OR Lansky PS 70100 % ( &lt; 16 year old ) LVEF &gt; 50 % rest SGOT &lt; 3 time upper limit normal Bilirubin &lt; 2.0 mg/dL ( unless liver involved disease ) Creatinine normal AND/OR creatinine clearance &gt; 60 mL/min Lung diffusion capacity &gt; 50 % predict ( correct hemoglobin ) OR asymptomatic room air oxygen saturation ≥ 98 % Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active uncontrolled viral , bacterial , fungal infection No HIV1 2 positivity PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior therapy 100 mg/m² melphalan No prior highdose chemotherapy require autologous stem cell rescue No prior radiotherapy &gt; 50 % pelvic marrow space</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
</DOC>